Your browser doesn't support javascript.
loading
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.
Halwani, Ahmad S; Panizo, Carlos; Isufi, Iris; Herrera, Alex F; Okada, Craig Y; Cull, Elizabeth H; Kis, Bela; Chaves, Jorge M; Bartlett, Nancy L; Ai, Weiyun; de la Cruz-Merino, Luis; Bryan, Locke J; Houot, Roch; Linton, Kim; Briones, Javier; Chau, Ian; von Keudell, Gottfried R; Lu, Hailing; Yakovich, Adam; Chen, Michael; Meulen Jh, Ter; Yurasov, Sergey; Hsu, Frank J; Flowers, Christopher R.
Afiliação
  • Halwani AS; Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Panizo C; Department of Hematology and Hemotherapy, Clínica Universidad de Navarra; Instituto de Investigación Sanitaria de Navarra, University of Navarra, Pamplona, Spain.
  • Isufi I; Department of Medicine (Hematology), Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Herrera AF; Department of Hematology & Hematopoietic Cell Transportation, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Okada CY; Division of Hematology and Hematologic Malignancies, Oregon Health and Science University, Portland, OR, USA.
  • Cull EH; Medical Oncology and Hematology Oncology, Prisma Health, Greenville, SC, USA.
  • Kis B; Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, FL, USA.
  • Chaves JM; Medical Oncology, Northwest Medical Specialties, Tacoma, WA, USA.
  • Bartlett NL; Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
  • Ai W; Department of Medicine (Hematology/Oncology), Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • de la Cruz-Merino L; Department of Clinical Oncology, Hospital Universitario Virgen Macarena, Seville, Spain.
  • Bryan LJ; Department of Medicine, University of Seville, Seville, Spain.
  • Houot R; Department of Medicine, Augusta University, Augusta, GA, USA.
  • Linton K; Department of Hematology, CHU Rennes, University of Rennes, Rennes, France.
  • Briones J; Medical Oncology, The Christie NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom.
  • Chau I; Department of Hematology, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain.
  • von Keudell GR; Lymphoma Unit, Royal Marsden Hospital, London & Surrey, United Kingdom.
  • Lu H; Medical Oncology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
  • Yakovich A; Immune Design, South San Francisco, CA, USA.
  • Chen M; Immune Design, South San Francisco, CA, USA.
  • Meulen Jh T; Immune Design, South San Francisco, CA, USA.
  • Yurasov S; Immune Design, South San Francisco, CA, USA.
  • Hsu FJ; Obsidian Therapeutics, Inc., Cambridge, MA, USA.
  • Flowers CR; Immune Design, South San Francisco, CA, USA.
Leuk Lymphoma ; 63(4): 821-833, 2022 04.
Article em En | MEDLINE | ID: mdl-34865586
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Folicular / Receptor 4 Toll-Like Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Leuk Lymphoma Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Folicular / Receptor 4 Toll-Like Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Leuk Lymphoma Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos